Quantifying the use of the statin antilipemic drugs: Comparisons and contrasts between Nova Scotia, Canada, and Queensland, Australia

Clinical Therapeutics

Volumn 27, Issue 4, 2005, Pages 497-508

  Cooke, Charmaine ^a   Nissen, Lisa ^b   Sketris, Ingrid ^a   Tett, Susan E ^b  

^a DALHOUSIE UNIVERSITY   (Canada)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Antilipemic drugs; Drug utilization; International comparisons; Statins

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; AUSTRALIA; CANADA; COMPARATIVE STUDY; CONTROLLED STUDY; DATA BASE; DRUG COST; DRUG UTILIZATION; FEASIBILITY STUDY; FEMALE; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; HYPERLIPIDEMIA; MALE; METHODOLOGY; PENSIONER; PRESCRIPTION; QUANTITATIVE ANALYSIS; RECIPIENT; REIMBURSEMENT; SOCIAL SECURITY; STATISTICAL SIGNIFICANCE; WORLD HEALTH ORGANIZATION;

AGED; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DRUG UTILIZATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSURANCE, PHARMACEUTICAL SERVICES; MALE; NOVA SCOTIA; QUEENSLAND;

EID: 19544362369     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2005.04.009     Document Type: Article

References (55)

1. Sketris I.S., and Hill S. The Australian national publicly subsidized Pharmaceutical Benefits Scheme: Any lessons for Canada? Cant Clin Pharmacol. 5 1998 111 118
2. Birkett D.J., Mitchell A.S., and McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia Health Aff (Millwood) 20 2001 104 114
3. Tett S.E. A perspective on Australia's National Medicines Policy Cant Clin Pharmacol. 11 2004 e28 e38
4. Romanow R.J. Building on Values: The Future of Health Care in Canada 2002 Commission on the Future of Health Care in Canada Ottawa, Ont
5. Sketris I.S., Brown M.G., and Murphy A.L. Policy choices for Pharmacare: The need to examine benefit design, medication management strategies and evaluation Healthcare Papers 4 2004 36 45
6. Donelan K., Blendon R.J., and Schoen C. The elderly in five nations: The importance of universal coverage Health Aff (Millwood) 19 2000 226 235
7. Donnelly N., McManus P., Dudley J., and Hall W. Impact of increasing the re-supply interval on the seasonality of subsidised prescription use in Australia Aust N Z J Public Health 24 2000 603 606
8. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies Soc Sci Med. 45 1997 563 581
9. McManus P., Marley J., Birkett D.J., and Lindner J. Compliance with restrictions on the subsidized use of proton pump inhibitors in Australia Br J Clin Pharmacol. 46 1998 409 411
10. Rietveld A., and Haaijar-Ruskamp F. Policy options for cost containment of pharmaceuticals Int J Risk Saf Med 15 2002 29 54
11. Kirby M.J. Interim report on the state of health care system in Canada. The health of Canadians-The federal role Principles and Recommendations for Reform--Part I Vol 5 2002 Standing Senate Committee on Social Affairs, Science and Technology Ottawa, Ont
12. Jackevicius C.A., Anderson G.M., Leiter L., and Tu J.V. Use of the statins in patients after acute myocardial infarction: Does evidence change practice? Arch Intern Med. 161 2001 183 188
13. Braunstein J.B., Cheng A., and Cohn G. Lipid disorders. Justification of methods and goals of treatment Chest 120 2001 979 988
14. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial Lancet 360 2002 7 22
15. Kephart G., Sketris I., and MacLean D. Management of high blood cholesterol levels in Nova Scotian adults: Comparison with the NCEP II and European clinical practice guidelines Am J Manag Care 6 2000 1017 1028
16. LaRosa J.C., He J., and Vupputuri S. Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials JAMA 282 1999 2340 2346
17. Drug monitor: Top 10 therapeutic classes 2003
18. Australian Statistics on Medicines 1999-2000 Available at: Accessed January 28, 2005
19. Census. Available at: Statistics Canada Age and sex: Highlight tables Accessed February 3, 2005 2001
20. Australian Bureau of Statistics. Australian demographic statistics: Table 3101.0. Available at: http://www.abs.gov.au. Accessed January 20, 2005.
21. Health Canada. The growing burden of heart disease and stroke. Available at: http://www.cvdinfobase.ca/cvdbook/CVD_En03.pdf. Accessed February 3, 2005.
22. Cardiac Disease Surveillance On-Line. Statistics Canada Web site. Available at: http://www.dsol-smed.hc-sc.gc.ca/dsol-smed/cvd/c_dis_e.html. Accessed February 3, 2005.
23. Australian Institute of Health and Welfare. National mortality database and risk factor tables. Available at: http://www.aihw.gov.au/cvd. Accessed January 20, 2005.
24. Report of the Auditor General, 2004. Chapter 7. Available at: http://www.gov.ns.ca/audg/2004Decag.htm. Accessed January 20, 2005.
25. Australian Government Health Insurance Commission. HIC statistical reporting. Available at: http://www.hic.gov.au/providers/health_statistics/ statistical_reporting.htm. Accessed January 28, 2005.
26. Magrini N., Einarson T., and Vaccheri A. Use of lipid-lowering drugs from 1990 to 1994: An interna tional comparison among Australia, Finland, Italy (Emilia Romagna Region), Norway andSweden Eur J Clin Pharmacol. 53 1997 185 189
27. Merlo J., Wessling A., and Melander A. Comparison of dose standard units for drug utilisation studies Eur J Clin Pharmacol. 50 1996 27 30
28. Truter I., Wiseman I.C., and Kotze T.J. The defined daily dose as a measure of drug consumption in South Africa. A preliminary study S Afr Med J. 86 1996 675 679
29. Wertheimer A.I. The defined daily dose system [DDD] for drug utilization review Hosp Pharm. 21 1986 233 234
30. Wertheimer A.I. The defined daily dose system [DDD] for drug utilization review Hosp Pharm. 21 1986 239 241
31. Wertheimer A.I. The defined daily dose system [DDD] for drug utilization review Hosp Pharm. 21 1986 258
32. Sketris I.S., Metge C.J., and Ross J.L. The use of the World Health Organisation Anatomical Thera peutic Chemical/Defined Daily Dose methodology in Canada Drug Info J. 38 2004 15 27
33. World Health Organization Collaborating Centre for Drug Statistics Methodology ATC Index with DDDs 2001 World Health Organization Oslo, Norway
34. Bank of Canada. Exchange rates. Available at: http://www.bankocanada.ca/ en/exchange_avg_pdf.html. Accessed January 29, 2005.
35. Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Cerivastatin withdrawal: 10 August 2001. Available at: http://www.tga.gov.au/docs/html/cerivast.htm. Accessed January 28, 2005.
36. Leuflkens H.G., and Urquhart J. Variability in patterns of drug usage J Pharm Pharmacol. 46 Suppl 1 1994 433 437
37. Heerdink E.R., Urquhart J., and Leuflkens H.G. Changes in prescribed drug doses after market introduction Pharmacoepidemiol Drug Saf 11 2002 447 453
38. Stafford E. Paying to choose BMJ 328 2004 402
39. Collier J., and Iheanacho I. The pharmaceutical industry as an informant Lancet 360 2002 1405 1409
40. Choice of lipid-regulating drugs Med Lett Drugs Ther. 43 2001 43 48
41. Gardner D.M., Mintzes B., and Ostry A. Direct-to-consumer prescription drug advertising in Canada: Permission by default? CMAJ 169 2003 425 427
42. Larsen J., Vaccheri A., and Andersen M. Lack of adherence to lipid-lowering drug treatment. A comparison of utilization patterns in defined populations in Funen, Denmark and Bologna, Italy Br J Clin Pharmacol. 49 2000 463 471
43. Larsen J., Andersen M., Kragstrup J., and Gram L.F. Changes in the utilisation of lipid-lowering drugs over a 6-year period (1993-1998) in a Danish population Eur J Clin Pharmacol. 57 2001 343 348
44. Packham C., Pearson J., Robinson J., and Gray D. Use of statins in general practices, 1996-1998: Cross sectional study BMJ 320 2000 1583 1584
45. Baxter C., Jones R., and Corr L. Time trend analysis and variations in prescribing lipid lowering drugs in gen eral practice BMJ 317 1998 1134 1135
46. Majeed A., Moser K., and Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales J Public Health Med. 22 2000 275 279
47. Mantel-Teeuwisse A.K., Klungel O.H., and Verschuren W.M. Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated? Br J Clin Pharmacol. 53 2002 379 385
48. Bazalo G.R. Managed care trends in statin usage Manag Care 10 2001 48 50
49. Bazalo G.R. Managed care trends in statin usage Manag Care 10 2001 53 59
50. Levy A.R., O'Brien B.J., and McMullen E. Rapid increase in statins newly dispensed to Ontario seniors be tween 1994 and 2000 Cant Cardiol. 19 2003 665 669
51. Jackevicius C.A., Tu K., and Filate W.A. Canadian Cardiovascular Outcomes Research Team Trends in cardiovascular drug utilization and drug expenditures in Canada between 1996 and 2001 Can J Cardiol. 19 2003 1359 1366
52. 49. Metge CM, Kozyrskyj A, Dahl M, etal. Pharmaceuticals: Focussing on appropriate utilization. Available at: http://www.umanitoba.ca/centres/mchp/ reports/pdfs/pharma.pdf. Accessed January 26, 2005.
53. [published correction appears in BMJ. 2004;329:323] Walley T., Folino-Gallo P., Schwabe U., van Ganse E. EuroMedStat Group Variations and increase in use of statins across Europe: Data from administrative databases BMJ 328 2004 385 386
54. Taylor R.S., Drummond M.F., Salkeld G., and Sullivan S.D. Inclusion of cost effectiveness in licensing requirements of new drugs: The fourth hurdle BMJ 329 2004 972 975
55. Tamblyn R., Laprise R., and Hanley J.A. Adverse events associated with prescription drug cost-sharing among poor and elderly persons JAMA 285 2001 421 429